Health
Study: T-1249 benefits those with resistance to Fuzeon
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Study: T-1249 benefits those with resistance to Fuzeon
Study: T-1249 benefits those with resistance to Fuzeon
Study data presented Monday at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy show that Roche and Trimeris's second-generation experimental fusion inhibitor, T-1249, can reduce the HIV viral loads of patients who have developed resistance to the companies' first fusion inhibitor, Fuzeon. Data from a Phase I/II study of the experimental drug showed that it was effective in significantly reducing the viral loads of 73% of patients who developed resistance to Fuzeon. No serious drug-related side effects were reported by the study volunteers. "The results from this study of T-1249 demonstrate that fusion inhibitors constitute an expanding class of anti-HIV drugs with the potential to be used sequentially," said Dani Bolognesi, CEO at Trimeris. Next up are Phase II clinical trials, which will begin in 2004.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!